ATE524489T1 - Mutierte pseudomonas-exotoxine mit reduzierter antigenität - Google Patents
Mutierte pseudomonas-exotoxine mit reduzierter antigenitätInfo
- Publication number
- ATE524489T1 ATE524489T1 AT06788523T AT06788523T ATE524489T1 AT E524489 T1 ATE524489 T1 AT E524489T1 AT 06788523 T AT06788523 T AT 06788523T AT 06788523 T AT06788523 T AT 06788523T AT E524489 T1 ATE524489 T1 AT E524489T1
- Authority
- AT
- Austria
- Prior art keywords
- reduced
- antigenity
- pes
- pseudomonas exotoxins
- mutated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70379805P | 2005-07-29 | 2005-07-29 | |
PCT/US2006/028986 WO2007016150A2 (en) | 2005-07-29 | 2006-07-25 | Mutated pseudomonas exotoxins with reduced antigenicity |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE524489T1 true ATE524489T1 (de) | 2011-09-15 |
Family
ID=37709138
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06788523T ATE524489T1 (de) | 2005-07-29 | 2006-07-25 | Mutierte pseudomonas-exotoxine mit reduzierter antigenität |
Country Status (8)
Country | Link |
---|---|
US (1) | US8907060B2 (de) |
EP (6) | EP2332970B1 (de) |
AT (1) | ATE524489T1 (de) |
AU (1) | AU2006275865B2 (de) |
CA (2) | CA2616987C (de) |
ES (6) | ES2660026T3 (de) |
PL (3) | PL3006457T3 (de) |
WO (1) | WO2007016150A2 (de) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7989322B2 (en) | 2007-02-07 | 2011-08-02 | Micron Technology, Inc. | Methods of forming transistors |
WO2008109005A2 (en) * | 2007-03-02 | 2008-09-12 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of anti-cd22 immunotoxins and protein-synthesis-inhibiting chemotherapeutic agents in treatment of b cell cancers |
DK2197903T3 (en) * | 2007-09-04 | 2015-01-05 | Us Gov Health & Human Serv | Deletions in Domain II from Pseudomonas exotoxin A that reduce non-specific TOXICITY |
WO2011031441A1 (en) | 2009-08-28 | 2011-03-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Therapy with a chimeric molecule and a pro-apoptotic agent |
EP2475398B1 (de) * | 2009-09-11 | 2015-05-20 | The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services | Verbessertes pseudomonas-exotoxin a mit verminderter immunogenität |
WO2011100455A1 (en) | 2010-02-12 | 2011-08-18 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Inhibition of antibody responses to foreign proteins |
SG10202009967TA (en) | 2010-07-30 | 2020-11-27 | Medimmune Llc | Method for purifying active polypeptides or immunoconjugates |
ES2656943T3 (es) | 2010-09-15 | 2018-03-01 | Randall J. Mrsny | Sistema y métodos de suministro de agentes bioactivos usando secuencias de transporte derivadas de toxina bacteriana |
US11246915B2 (en) | 2010-09-15 | 2022-02-15 | Applied Molecular Transport Inc. | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo |
CN105968209B (zh) | 2011-04-19 | 2021-08-03 | 美国政府(由卫生和人类服务部的部长所代表) | 对磷脂酰肌醇蛋白聚糖3特异的人单克隆抗体及其用途 |
MX2013012905A (es) | 2011-05-06 | 2014-04-25 | Us Gov Health & Human Serv | Inmunotoxina recombinante dirigida a la mesotelina. |
EP2718308B1 (de) | 2011-06-09 | 2017-05-17 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Pseudomonas exotoxin a mit weniger immunogenen t-zell- und/oder b-zellepitopen |
US8932586B2 (en) * | 2011-09-06 | 2015-01-13 | Intrexon Corporation | Modified forms of Pseudomonas exotoxin A |
WO2013039916A1 (en) | 2011-09-12 | 2013-03-21 | The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services | Compositions for and methods of treatment and enhanced detection of non-pituitary tumors |
EP2755993B1 (de) | 2011-09-16 | 2017-11-08 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Pseudomonas exotoxin a mit weniger immunogenen b-zellepitopen |
EP2768863B1 (de) | 2011-10-20 | 2017-09-27 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Chimäre anti-cd22-antigenrezeptoren |
PL397167A1 (pl) | 2011-11-28 | 2013-06-10 | Adamed Spólka Z Ograniczona Odpowiedzialnoscia | Przeciwnowotworowe bialko fuzyjne |
WO2013181543A1 (en) | 2012-06-01 | 2013-12-05 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | High-affinity monoclonal antibodies to glypican-3 and use thereof |
CA2882753C (en) | 2012-08-21 | 2021-08-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mesothelin domain-specific monoclonal antibodies and use thereof |
JP6307085B2 (ja) | 2012-09-27 | 2018-04-04 | ザ・ユナイテッド・ステイツ・オブ・アメリカ・アズ・リプリゼンテッド・バイ・ザ・セクレタリー・デパートメント・オブ・ヘルス・アンド・ヒューマン・サービシーズThe United States of America,as represented by the Secretary,Department of Health and Human Services | メソテリン抗体および強力な抗腫瘍活性を惹起するための方法 |
AU2013343667A1 (en) | 2012-11-08 | 2015-04-02 | F. Hoffmann-La Roche Ag | HER3 antigen binding proteins binding to the beta-hairpin of HER3 |
AU2013361235B2 (en) | 2012-12-20 | 2018-07-26 | Medimmune, Llc | Methods of producing immunoconjugates |
AU2014329437B2 (en) | 2013-10-06 | 2018-10-18 | F. Hoffmann-La Roche Ag | Modified Pseudomonas exotoxin A |
CA2925393C (en) | 2013-10-11 | 2023-03-07 | Dimiter Dimitrov | Tem8 antibodies and their use |
US20160280798A1 (en) | 2013-11-06 | 2016-09-29 | The United States Of America, As Represented By The Secretary Department Of Health & Human Service | Alk antibodies, conjugates, and chimeric antigen receptors, and their use |
JP6814634B2 (ja) | 2014-02-05 | 2021-01-20 | モレキュラー テンプレーツ,インク.Molecular Templates, Inc. | リボ毒性の一時的な減少に基づき、細胞毒性組換えポリペプチドをスクリーニングし、選択し、同定する方法 |
PL3139965T3 (pl) | 2014-05-07 | 2022-01-31 | Applied Molecular Transport Inc. | Cząsteczki fuzyjne pochodzące z toksyny cholix do doustnego dostarczania ładunku biologicznie czynnego |
JP6811706B2 (ja) | 2014-07-31 | 2021-01-13 | ザ ホンコン ユニヴァーシティ オブ サイエンス アンド テクノロジー | Epha4に対するヒトモノクローナル抗体及びそれらの使用 |
WO2016146833A1 (en) | 2015-03-19 | 2016-09-22 | F. Hoffmann-La Roche Ag | Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance |
EP3184547A1 (de) | 2015-10-29 | 2017-06-28 | F. Hoffmann-La Roche AG | Anti-tpbg-antikörper und verfahren zur verwendung |
CA3005042A1 (en) | 2015-11-13 | 2017-05-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-bcma polypeptides and proteins |
WO2017196847A1 (en) | 2016-05-10 | 2017-11-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens |
WO2017214182A1 (en) | 2016-06-07 | 2017-12-14 | The United States Of America. As Represented By The Secretary, Department Of Health & Human Services | Fully human antibody targeting pdi for cancer immunotherapy |
US11066479B2 (en) | 2016-08-02 | 2021-07-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies targeting glypican-2 (GPC2) and use thereof |
CA3045902A1 (en) | 2016-12-21 | 2018-06-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies specific for flt3 and uses thereof |
WO2018213612A1 (en) | 2017-05-18 | 2018-11-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mesothelin polypeptides and proteins |
WO2018213064A1 (en) | 2017-05-19 | 2018-11-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibody targeting tnfer2 for cancer immunotherapy |
WO2019006280A1 (en) | 2017-06-30 | 2019-01-03 | Lentigen Technology, Inc. | HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO CD33 AND METHODS OF USE |
WO2019005208A1 (en) | 2017-06-30 | 2019-01-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY |
WO2019055955A1 (en) | 2017-09-18 | 2019-03-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | IMMUNOTOXINS WITH ALBUMIN BINDING DOMAIN |
HUE059330T2 (hu) | 2018-03-08 | 2022-11-28 | Applied Molecular Transport Inc | Toxinból származó bejuttatási konstrukciók orális beadásra |
JP7459043B2 (ja) | 2018-07-12 | 2024-04-01 | ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 親和性成熟cd22特異的モノクローナル抗体およびその使用 |
AU2019317565A1 (en) | 2018-08-08 | 2021-02-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | High affinity monoclonal antibodies targeting glypican-2 and uses thereof |
CN113347997A (zh) | 2018-11-07 | 2021-09-03 | 应用分子运输公司 | 用于经口递送异源有效载荷的Cholix衍生的携带体 |
US20220064324A1 (en) | 2019-01-08 | 2022-03-03 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Cross species single domain antibodies targeting mesothelin for treating solid tumors |
EP3883971A1 (de) | 2019-01-22 | 2021-09-29 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Hochaffine monoklonale antikörper gegen glypican-1 und verfahren zur verwendung |
CN114269783B (zh) | 2019-07-02 | 2024-03-26 | 美国政府(由卫生和人类服务部的部长所代表) | 结合egfrviii的单克隆抗体及其应用 |
TW202120521A (zh) | 2019-08-16 | 2021-06-01 | 美商應用分子運輸公司 | 組合物、配方及介白素生產及純化 |
CA3156761A1 (en) | 2019-10-22 | 2021-04-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | High affinity nanobodies targeting b7h3 (cd276) for treating multiple solid tumors |
WO2021097289A1 (en) | 2019-11-15 | 2021-05-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Pegylated recombinant immunotoxins |
WO2022093745A1 (en) | 2020-10-26 | 2022-05-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies targeting sars coronavirus spike protein and uses thereof |
EP4269447A4 (de) | 2020-12-22 | 2024-07-24 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Komplex aus anti-il-4r-antikörper oder antigenbindendem fragment davon und medizinische verwendung davon |
US20240218055A1 (en) | 2021-04-29 | 2024-07-04 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Lassa virus-specific nanobodies and methods of their use |
US20240270851A1 (en) | 2021-06-09 | 2024-08-15 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Cross species single domain antibodies targeting pd-l1 for treating solid tumors |
WO2023076881A1 (en) | 2021-10-26 | 2023-05-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies targeting the s2 subunit of sars-cov-2 spike protein |
CA3240254A1 (en) | 2021-12-17 | 2023-06-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mesothelin polypeptides, proteins, and chimeric antigen receptors |
WO2024050399A1 (en) | 2022-09-01 | 2024-03-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes |
WO2024104584A1 (en) | 2022-11-17 | 2024-05-23 | University Of Cape Town | Deimmunized pseudomonas exotoxin a |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
US4501728A (en) * | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US4957735A (en) | 1984-06-12 | 1990-09-18 | The University Of Tennessee Research Corporation | Target-sensitive immunoliposomes- preparation and characterization |
US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
US4892827A (en) | 1986-09-24 | 1990-01-09 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
US5055303A (en) | 1989-01-31 | 1991-10-08 | Kv Pharmaceutical Company | Solid controlled release bioadherent emulsions |
US5621078A (en) * | 1989-03-22 | 1997-04-15 | Merck & Co., Inc. | Modified pseudomonas exotoxin PE40 |
DE3920358A1 (de) * | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5271961A (en) | 1989-11-06 | 1993-12-21 | Alkermes Controlled Therapeutics, Inc. | Method for producing protein microspheres |
US5188837A (en) | 1989-11-13 | 1993-02-23 | Nova Pharmaceutical Corporation | Lipsopheres for controlled delivery of substances |
US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
JP2665827B2 (ja) | 1990-05-11 | 1997-10-22 | アメリカ合衆国 | 低―動物毒性と高殺細胞活性の改良シュードモナス外毒素 |
US5608039A (en) | 1990-10-12 | 1997-03-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Single chain B3 antibody fusion proteins and their uses |
US5254342A (en) | 1991-09-30 | 1993-10-19 | University Of Southern California | Compositions and methods for enhanced transepithelial and transendothelial transport or active agents |
CA2122732C (en) | 1991-11-25 | 2008-04-08 | Marc D. Whitlow | Multivalent antigen-binding proteins |
JPH07507768A (ja) | 1992-03-12 | 1995-08-31 | アルカーメス コントロールド セラピューティクス,インコーポレイテッド | Acth含有マイクロスフェアの制御放出 |
DE69333951D1 (de) | 1992-06-18 | 2006-02-02 | Us Gov Health & Human Serv | Rekombinantes pseudomonas exotoxin mit gesteigerter aktivität |
US5534496A (en) | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
US5747654A (en) * | 1993-06-14 | 1998-05-05 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant disulfide-stabilized polypeptide fragments having binding specificity |
US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
US5888773A (en) | 1994-08-17 | 1999-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Method of producing single-chain Fv molecules |
US6518061B1 (en) * | 1995-03-15 | 2003-02-11 | The United States Of America As Represented By The Department Of Health And Human Services | IL-13 receptor specific chimeric proteins and uses thereof |
JPH11515013A (ja) | 1995-10-27 | 1999-12-21 | メルク エンド カンパニー インコーポレーテッド | 合成複合ワクチンの免疫原性担体としてのシュードモナスエクソトキシン |
JP2001504334A (ja) * | 1996-11-06 | 2001-04-03 | アメリカ合衆国 | プロテアーゼ活性化可能なPseudomonas体外毒素A様プロタンパク質 |
US6296843B1 (en) | 1998-04-03 | 2001-10-02 | The Penn State Research Foundation | Mutagenized IL 13-based chimeric molecules |
US20020142000A1 (en) * | 1999-01-15 | 2002-10-03 | Digan Mary Ellen | Anti-CD3 immunotoxins and therapeutic uses therefor |
US7081518B1 (en) * | 1999-05-27 | 2006-07-25 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-mesothelin antibodies having high binding affinity |
EP1263785A2 (de) | 1999-11-11 | 2002-12-11 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Il-13 mutante und verfahren davon |
EP1330766A2 (de) | 2000-07-10 | 2003-07-30 | Xencor | Verfahren zum entwerfen von proteinbibliotheken mit modifizierter immunogenität |
ZA200305980B (en) | 2001-02-12 | 2007-01-31 | Res Dev Foundation | Modified proteins, designer toxins, and methods of making thereof |
US20030113350A1 (en) * | 2001-09-19 | 2003-06-19 | Fattom Ali I. | Glycoconjugate vaccines for use in immune-compromised populations |
ATE468348T1 (de) * | 2001-09-26 | 2010-06-15 | Government Of The Us Secretary | Mutierte anti-cd22-antikörper mit erhöhter affinität zu cd22-exprimierenden leukämiezellen |
EP1448237A1 (de) | 2001-11-09 | 2004-08-25 | Neopharm, Inc. | Selektive behandlung von il-13-exprimierenden tumoren |
CA2547165C (en) | 2003-11-25 | 2014-07-08 | Ira H. Pastan | Mutated anti-cd22 antibodies and immunoconjugates |
US8524241B2 (en) * | 2007-07-20 | 2013-09-03 | The General Hospital Corporation | Fusion proteins comprising a fragment of Vibrio cholerae exotoxin A |
DK2197903T3 (en) * | 2007-09-04 | 2015-01-05 | Us Gov Health & Human Serv | Deletions in Domain II from Pseudomonas exotoxin A that reduce non-specific TOXICITY |
EP2411416A1 (de) * | 2009-03-24 | 2012-02-01 | The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services | Anti-mesothelin-antikörper |
WO2011031441A1 (en) * | 2009-08-28 | 2011-03-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Therapy with a chimeric molecule and a pro-apoptotic agent |
EP2475398B1 (de) * | 2009-09-11 | 2015-05-20 | The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services | Verbessertes pseudomonas-exotoxin a mit verminderter immunogenität |
CN103068850A (zh) * | 2010-05-26 | 2013-04-24 | 明尼苏达大学评议会 | 单链可变片段抗-cd133抗体及其用途 |
EP2718308B1 (de) * | 2011-06-09 | 2017-05-17 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Pseudomonas exotoxin a mit weniger immunogenen t-zell- und/oder b-zellepitopen |
-
2006
- 2006-07-25 CA CA2616987A patent/CA2616987C/en active Active
- 2006-07-25 EP EP10179539.1A patent/EP2332970B1/de active Active
- 2006-07-25 AU AU2006275865A patent/AU2006275865B2/en active Active
- 2006-07-25 PL PL15191391T patent/PL3006457T3/pl unknown
- 2006-07-25 ES ES15191395.1T patent/ES2660026T3/es active Active
- 2006-07-25 EP EP15191395.1A patent/EP3006458B1/de active Active
- 2006-07-25 WO PCT/US2006/028986 patent/WO2007016150A2/en active Application Filing
- 2006-07-25 PL PL15191388T patent/PL3006456T3/pl unknown
- 2006-07-25 PL PL15191395T patent/PL3006458T3/pl unknown
- 2006-07-25 ES ES06788523T patent/ES2372537T3/es active Active
- 2006-07-25 US US11/997,202 patent/US8907060B2/en active Active
- 2006-07-25 EP EP10179520.1A patent/EP2311854B1/de active Active
- 2006-07-25 EP EP06788523A patent/EP1910407B1/de active Active
- 2006-07-25 AT AT06788523T patent/ATE524489T1/de not_active IP Right Cessation
- 2006-07-25 CA CA2941466A patent/CA2941466C/en active Active
- 2006-07-25 EP EP15191388.6A patent/EP3006456B1/de active Active
- 2006-07-25 ES ES10179539.1T patent/ES2564092T3/es active Active
- 2006-07-25 ES ES15191388T patent/ES2702650T3/es active Active
- 2006-07-25 ES ES10179520T patent/ES2410783T3/es active Active
- 2006-07-25 ES ES15191391.0T patent/ES2659039T3/es active Active
- 2006-07-25 EP EP15191391.0A patent/EP3006457B1/de active Active
Also Published As
Publication number | Publication date |
---|---|
PL3006457T3 (pl) | 2018-05-30 |
CA2616987C (en) | 2016-10-11 |
PL3006456T3 (pl) | 2019-05-31 |
EP1910407B1 (de) | 2011-09-14 |
EP2311854B1 (de) | 2013-04-17 |
WO2007016150A3 (en) | 2007-08-09 |
EP3006456B1 (de) | 2018-09-19 |
ES2659039T3 (es) | 2018-03-13 |
PL3006458T3 (pl) | 2018-05-30 |
ES2372537T3 (es) | 2012-01-23 |
ES2410783T3 (es) | 2013-07-03 |
CA2941466C (en) | 2019-12-03 |
EP2311854A1 (de) | 2011-04-20 |
EP3006458A1 (de) | 2016-04-13 |
EP2332970A2 (de) | 2011-06-15 |
ES2660026T3 (es) | 2018-03-20 |
ES2702650T3 (es) | 2019-03-04 |
EP3006457A1 (de) | 2016-04-13 |
CA2941466A1 (en) | 2007-02-08 |
WO2007016150A2 (en) | 2007-02-08 |
US8907060B2 (en) | 2014-12-09 |
ES2564092T3 (es) | 2016-03-17 |
EP1910407A2 (de) | 2008-04-16 |
EP3006458B1 (de) | 2017-11-22 |
EP3006457B1 (de) | 2017-11-22 |
CA2616987A1 (en) | 2007-02-08 |
EP2332970A3 (de) | 2011-09-14 |
EP3006456A1 (de) | 2016-04-13 |
AU2006275865A1 (en) | 2007-02-08 |
AU2006275865B2 (en) | 2012-06-28 |
EP2332970B1 (de) | 2015-12-23 |
US20090142341A1 (en) | 2009-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE524489T1 (de) | Mutierte pseudomonas-exotoxine mit reduzierter antigenität | |
LTPA2017022I1 (lt) | Antikūnai prieš Clostridium difficile toksinus ir jų panaudojimas | |
PH12018500657A1 (en) | Optimized variants of anti-vegf antibodies | |
DK2135881T3 (da) | Antistoffer, som binder til det tumor-associerede antigen TAT10772, til diagnose og behandling af tumor | |
DE602006021296D1 (de) | Monoklonale antikörper und einzelkettenantikörper fragments gegen das zelloberflächen prostataspezifische membranantigen | |
WO2006089230A3 (en) | Human monoclonal antibodies to prostate specific membrane antigen (psma) | |
HK1109636A1 (en) | Human antibodies and proteins | |
WO2008121615A3 (en) | Antibody formulation | |
EA200801174A1 (ru) | Антитела-миметики glp-2, полипептиды, композиции, способы и применения | |
CL2013001279A1 (es) | Anticuerpo humano aislado o fragmento de union a antigeno del mismo que se une especificamente y neutraliza la actividad del ligando 1a de tipo tnf humano (htl1a); molecula de acido nucleico que lo codifica; vector de expresion; metodo de produccion; composicion farmaceutica que lo comprende; y su uso. | |
DK2681244T3 (da) | Cea-antistoffer | |
MY163480A (en) | Sclerostin binding agents | |
NO20083397L (no) | Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse | |
EA200702278A1 (ru) | Антитела, специфичные в отношении tgf-бета 1 | |
MX2010010776A (es) | Fusiones y conjugados de farmaco. | |
WO2009008916A3 (en) | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins | |
WO2016172551A3 (en) | Methods of identifying bacteria comprising binding polypeptides | |
EA201990218A1 (ru) | Антитела с низкой иммуногенностью и их применения | |
WO2014150748A3 (en) | Stabilized single human cd4 domains and fusion proteins | |
ATE486127T1 (de) | Wiederherstellung der aktivität von 5- enolpyruvylshikimat-3-phosphat-synthase durch fragmentkomplementierung | |
AR098953A1 (es) | Anticuerpo anti-adam17 (proteína desintegrina y metaloproteinasa-17) y su uso para el tratamiento de cáncer | |
WO2012149406A3 (en) | Assessing and treating humans with long qt syndrome | |
WO2006136892A3 (de) | Neuartige cherlasky - fusionsproteine enthalten antikorperbindeproteine oder ihre regionen | |
WO2006123122A3 (en) | Psk- i and its modulators for the treatment/diagnosis of cancer | |
UA103306C2 (en) | Normal;heading 1;heading 2;heading 3;HUMAN C-FMS ANTIGEN BINDING PROTEINS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |